Ads
related to: rituximab for ms patients side effects- Patient Stories
See What Real Patients
Are Saying About This Treatment.
- Treatment FAQs
See Frequently Asked
Questions. Get The Answers.
- Financial Resources
See Financial & Savings Info.
Learn About Savings Options.
- Patient Resources
Download Resources To
Learn More About Treatment.
- Clinical Results
View The Results Of
Clinical Studies Here.
- Relapsing MS Treatment
Learn About A RMS
Treatment Option.
- Patient Stories
Search results
Results From The WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Around 20% of MS patients with PML die, while most of the remaining are importantly disabled. [36] During clinical trials fingolimod gave rise to side effects such as hypertension and bradycardia, macular edema, elevated liver enzymes or reduction in lymphocyte levels. [39] [14] Teriflunomide is considered a very safe drug.
Multiple sclerosis (MS) is an autoimmune disorder in which the immune system attacks and destroys the myelin sheath of nerve cells. It most commonly strikes people between the ages of 20 and 40.
A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response.TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their ...
A small, short-duration clinical trial [103] with MS patients was conducted at the University of California, San Francisco. In October 2007 data was presented at the European Congress of MS in Prague regarding safety findings of a pilot study of low dose naltrexone therapy in multiple sclerosis by neurological researchers in Milan, Italy. [104]
As in multiple sclerosis, another demyelinating condition, it is not possible to predict with certainty how CIDP will affect patients over time. The pattern of relapses and remissions varies greatly with each patient. A period of relapse can be very disturbing, but many patients make significant recoveries. [citation needed]
Ads
related to: rituximab for ms patients side effects